# Pizarra — PT-pseudo_17f110c9e142 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_17f110c9e142
Task: 1

Encounter: Urology - outpatient on 24 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.171 ng/mL²
  - PSA velocity: 0.72 ng/mL/yr
  - Prior PSA: 5.3 ng/mL
  - Prostate volume: 40.33 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8314881 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 6.9 ng/mL. PI-RADS 5. PSAD 0.17. Prostate volume 40 mL. DRE nodus. csPCa 0.83.

Vitals: weight 70 kg, height 177 cm, BMI 22.3, BP 124/70 mmHg, HR 82 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2023).

Chief complaint: Specialist reassessment is requested due to a previous prostate cancer diagnosis coupled with a recent PSA increase to 6.9 ng/mL.

History: A 67-year-old retired warehouse worker initiated evaluation for prostate anomalies in 2024 after an initial PSA spike. Currently married yet residing independently, he relies on his adult son for emergency contact and his daughter for managing correspondence. Moderate lower urinary tract symptoms, notably nocturia and a diminished stream, yield an IPSS score of 17. Daily habits encompass a 20-minute walking routine and moderate alcohol intake averaging 16 units weekly. Recent outpatient screenings for hearing and actinic keratosis remain stable. He explicitly denies unexplained weight loss, skeletal pain, or haematuria, maintaining full independence in daily activities. Status: Ex-smoker (10 pack-yr, quit 2023).

Physical examination: Per rectum: Nodus DRE identifies a discrete, firm mass situated in the right peripheral zone, aligning with a cT2 classification. The remainder of the gland demonstrates symmetrical enlargement without additional abnormalities. Systemic assessment shows normal cardiorespiratory parameters. The individual maintains a well-nourished appearance and demonstrates unassisted mobility.

Patient info: retired warehouse worker; Married; Lives alone.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 16 units / week; exercise Walking 20 min/day; IPSS score: 17/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Dermatology — actinic keratosis check.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.50 +/- 0.18   (95% CI 0.15-0.85)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.18  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 1.00 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and patient agreement regarding the prior diagnosis?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with the current findings (PI-RADS 5, rising PSA), warrants a re-biopsy or deferral, as the visible panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context of the PI-RADS 5 score in conjunction with the prior positive biopsy status.
The prior did not weigh the specific PSA velocity (0.72 ng/mL/yr) or the specific PSA density (0.171 ng/mL²), which are critical risk factors that the guideline search suggests interact with PI-RADS scores.
The prior did not account for the guideline's emphasis on the need to check the prior grade documentation and MRI comparison, which is the core requirement for the protocol expert.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a 50% probability, which is a 'discuss' tier, indicating the panel is genuinely inconclusive. This is wrong because the guideline search suggests that PI-RADS 5 lesions are associated with an 83% detection rate of csPCa, which strongly pushes the decision towards biopsy, contradicting the prior's neutrality.
The prior failed to account for the potential contradiction: a high csPCa probability (0.8314881) versus the DRE finding of a nodule, which the protocol expert noted is insufficient without retrieved documents.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior diagnosis?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior diagnosis?

GUIDELINE ANCHOR
The guideline search indicates that PI-RADS 5 lesions have an 83% detection rate of csPCa, which constrains the decision by suggesting a strong consideration for biopsy.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Prostate multiparametric MRI | Date: 03 Feb 2025 | Institution: Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)
PI-RADS 5 lesion in the right peripheral zone.
The lesion measures roughly 15 x 12 x 10 mm and shows restricted diffusion on DWI.
csPCa predicted probability 0.8314881.

get_psa_trend
{"date": "Oct 2022", "val": 0.7}, {"date": "Dec 2023", "val": 1.8}, {"date": "Feb 2025", "val": 6.9}
The PSA trend shows a significant rise from 1.8 ng/mL in Dec 2023 to 6.9 ng/mL in Feb 2025.

get_previous_notes
{"date": "29 Jun 2024", "author": "Dr. P. van Dijk (GP)", "text": "Initial workup commenced in late 2023 after a PSA reading of 5.3 ng/mL led to a transrectal biopsy, which confirmed Gleason 3+4 malignancy. Ongoing active surveillance has tracked his biomarker trajectory. The latest assay, recorded in February 2025, indicates an upward trend to 6.9 ng/mL, driving this specialist consultation for comprehensive reassessment."}
The prior biopsy confirmed Gleason 3+4 malignancy. The patient is on an active surveillance protocol.

NOT RETRIEVED
laboratory_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no immediate question arose from the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PI-RADS 5 classification on the right peripheral zone lesion.
- Significant rising PSA trend from 1.8 ng/mL (Dec 2023) to 6.9 ng/mL (Feb 2025).
- Prior biopsy confirmed Gleason 3+4 malignancy, suggesting potential for progression or recurrence.

AGAINST sampling this patient now:
- Prior biopsy confirmed Gleason 3+4 malignancy, which is already characterized.

WHERE THIS LEANS
The combined evidence strongly suggests a need for further tissue characterization given the high-risk MRI finding and the rising PSA, despite the prior diagnosis.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents (MRI report, PSA trend, previous notes) provided sufficient evidence to conclude that the high-risk MRI finding and rising PSA trend warrant a biopsy, despite the prior positive biopsy.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context of the PI-RADS 5 score in conjunction with the prior positive biopsy status.
The prior did not weigh the specific PSA velocity (0.72 ng/mL/yr) or the specific PSA density (0.171 ng/mL²), which are critical risk factors that the guideline search suggests interact with PI-RADS scores.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a 50% probability, which is a 'discuss' tier, indicating the panel is genuinely inconclusive. This is wrong because the guideline search suggests that PI-RADS 5 lesions are associated with an 83% detection rate of csPCa, which strongly pushes the decision towards biopsy, contradicting the prior's neutrality.
The prior failed to account for the potential contradiction: a high csPCa probability (0.8314881) versus the DRE finding of a nodule, which the protocol expert noted is insufficient without retrieved documents.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior diagnosis?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior diagnosis?

GUIDELINE ANCHOR
The guideline search indicates that PI-RADS 5 lesions have an 83% detection rate of csPCa, which constrains the decision by suggesting a strong consideration for biopsy.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Prostate multiparametric MRI | Date: 03 Feb 2025 | Institution: Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)
The lesion measures roughly 15 x 12 x 10 mm and shows restricted diffusion on DWI. csPCa predicted probability 0.8314881.

get_psa_trend
{"date": "Oct 2022", "val": 0.7}, {"date": "Dec 2023", "val": 1.8}, {"date": "Feb 2025", "val": 6.9}
The PSA trend shows a significant rise from 1.8 ng/mL in Dec 2023 to 6.9 ng/mL in Feb 2025.

get_previous_notes
{"date": "29 Jun 2024", "author": "Dr. P. van Dijk (GP)", "text": "Initial workup commenced in late 2023 after a PSA reading of 5.3 ng/mL led to a transrectal biopsy, which confirmed Gleason 3+4 malignancy. Ongoing active surveillance has tracked his biomarker trajectory. The latest assay, recorded in February 2025, indicates an upward trend to 6.9 ng/mL, driving this specialist consultation for comprehensive reassessment."}

NOT RETRIEVED
laboratory_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no immediate question arose from the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PI-RADS 5 classification on the right peripheral zone lesion.
- Significant rising PSA trend from 1.8 ng/mL (Dec 2023) to 6.9 ng/mL (Feb 2025).
- Prior biopsy confirmed Gleason 3+4 malignancy, suggesting potential for progression or recurrence.

AGAINST sampling this patient now:
- Prior biopsy confirmed Gleason 3+4 malignancy, which is already characterized.

WHERE THIS LEANS
The combined evidence strongly suggests a need for further tissue characterization given the high-risk MRI finding and the rising PSA, despite the prior diagnosis.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents (MRI report, PSA trend, previous notes) provided sufficient evidence to conclude that the high-risk MRI finding and rising PSA trend warrant a biopsy, despite the prior positive biopsy. The disagreement remains about the interpretation of this evidence.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The decision leans towards biopsy because the retrieved evidence showed a PI-RADS 5 lesion and a significant rising PSA trend from 1.8 ng/mL to 6.9 ng/mL, which strongly supports further tissue characterization despite the prior positive biopsy. The statistical prior suggested deferral, but the retrieved documents, specifically the rising PSA trajectory and high PI-RADS score, overturned this by providing a clear indication for sampling. The conference resolved the split by accepting the evidence-based recommendation over the prior's suggestion.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
